Abstract: The disclosure provides methods of treating, identifying and/or selecting for treatment a subject having a cancer in which an immune checkpoint protein is upregulated. In certain embodiments, the methods for treating cancer in a subject in need thereof comprise administering to the subject: (a) a therapeutically effective amount of an EZH2 inhibitor and (b) a therapeutically effective amount of an immune checkpoint inhibitor. In certain embodiments of the methods of the disclosure, the EZH2 inhibitor is tazemetostat.

Abstract: The disclosure provides methods of treating, identifying and/or selecting for treatment a subject having a cancer in which an immune checkpoint protein is upregulated. In certain embodiments, the methods for treating cancer in a subject in need thereof comprise administering to the subject: (a) a therapeutically effective amount of an EZH2 inhibitor and (b) a therapeutically effective amount of an immune checkpoint inhibitor. In certain embodiments of the methods of the disclosure, the EZH2 inhibitor is tazemetostat.

Abstract: A package includes a first panel and a second panel. The first and second panels are sealed to each other to form a pouch (200). The pouch includes a main section and a channel section. The package further includes a product disposed within the pouch. The product is capable of flowing from the main section through the channel section to a tip (212) of the pouch. The pouch includes a valve (224) that has a curve extending transversely across the channel section. The curve is configured such that, when the product flows through the curve, the product flows by a convex side of the first panel in the curve and a concave side of the second panel in the curve.

Abstract: The disclosure provides methods of treating, identifying and/or selecting for treatment a subject having a cancer in which an immune checkpoint protein is upregulated. In certain embodiments, the methods for treating cancer in a subject in need thereof comprise administering to the subject: (a) a therapeutically effective amount of an EZH2 inhibitor and (b) a therapeutically effective amount of an immune checkpoint inhibitor. In certain embodiments of the methods of the disclosure, the EZH2 inhibitor is tazemetostat.

Abstract: Apparatus for a manually-powered wheelchair comprising a frame and first and second wheel rotatably coupled to the frame. Each wheel includes a hand rim and a drive wheel. For each of the first and second wheels, a multiple speed transmission coupled to the wheel comprises a transmission output coupled to the drive wheel, a transmission input coupled to the hand rim, and at least two gears selectively coupling the transmission output to the transmission input. The transmission allows the drive wheel and the hand rim to rotate concentrically with one another but at different speeds. A selector is provided for selecting one of the at least two gears. A controller controls the selector to operate the transmission for the first and/or second wheel.

Abstract: A geared wheel system for minimizing backlash is functionally coupled to a wheelchair and disclosed herein.